Built on Innovations in Central Nervous System (CNS) Diseases

Relmada Therapeutics addresses unmet needs in central nervous system (CNS) diseases - depression and chronic pain.

Who We Are

Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases.

Learn More About Relmada Therapeutics

Our Drug Candidates

REL-1017 (d-Methadone)

Novel NMDA receptor antagonist being developed for the treatment of depression and neuropathic pain.

View REL-1017 (d-Methadone)

Our Drug Candidates

REL-1015 (LevoCap ER)

Extended release, abuse resistant form of broad spectrum opioid levorphanol for treatment of chronic pain when an opioid is needed.

View REL-1015 (LevoCap ER)

Our Drug Candidates

REL-1028 (BuTab)

Novel oral formulations of modified release buprenorphine being developed for both chronic pain and opioid dependence indications.

View REL-1028 (BuTab)

Our Drug Candidates

REL-1021 (MepiGel)

Topical gel dosage form of local anesthetic mepivacaine for treatment of postherpetic neuralgia (PHN) and HIV-associated neuropathy.

View REL-1021 (MepiGel)

Our Leadership

Our efforts are guided by highly experienced drug development leadership and world-class scientific advisors that provide the expertise to efficiently advance product development.

Meet Our